當(dāng)前位置：首頁 SCI期刊 SCIE期刊醫(yī)學(xué) 中科院2區(qū) JCRQ1 期刊介紹(非官網(wǎng))

Biomedicine & PharmacotherapySCIE

國(guó)際簡(jiǎn)稱：BIOMED PHARMACOTHER 參考譯名：生物醫(yī)學(xué)與藥物治療

中科院分區(qū)
2區(qū)
CiteScore分區(qū)
Q1
JCR分區(qū)
Q1

基本信息：: ISSN：0753-3322; E-ISSN：1950-6007; 是否OA：未開放; 是否預(yù)警：是; TOP期刊：是

出版信息：: 出版地區(qū)：FRANCE; 出版商：Elsevier Masson; 出版語言：Multi-Language; 出版周期：Monthly; 出版年份：1982; 研究方向：醫(yī)學(xué)-藥學(xué)

評(píng)價(jià)信息：: 影響因子：6.9; H-index：78; CiteScore指數(shù)：11.9; SJR指數(shù)：1.493; SNIP指數(shù)：1.409

發(fā)文數(shù)據(jù)：: Gold OA文章占比：96.76%; 研究類文章占比：67.58%; 年發(fā)文量：1743; 自引率：0.0266...; 開源占比：0.9507; 出版撤稿占比：0.0061...; 出版國(guó)人文章占比：0.56; OA被引用占比：0.5432...

投稿咨詢加急見刊

英文簡(jiǎn)介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見問題

英文簡(jiǎn)介Biomedicine & Pharmacotherapy期刊介紹

Biomedicine & Pharmacotherapy is a multidisciplinary journal which publishes full-length, original research reports, reviews, and preliminary communications or letters to the editor which fall within the general scope of clinical and basic medicine and pharmacology.

The general fields of interest will include Cancer, Nutriceutics, Neurodegenerative, Cardiac and Infectious Diseases.

Special emphasis will be placed on studies of specific topics such as molecular mechanisms, gene regulation in normal and pathologic cells as well as susceptibility in response to oncogenic agents. Effects of drugs on preclinical and clinical pharmacology and the role of bacteria, viruses and parasites in animals and humans.

Brief reports of meetings, symposia and conferences will also be considered for publication as well as brief listings of scientific meetings or academic courses of interest to the readers

期刊簡(jiǎn)介Biomedicine & Pharmacotherapy期刊介紹

《Biomedicine & Pharmacotherapy》自1982出版以來，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個(gè)領(lǐng)域的原創(chuàng)研究提供一個(gè)展示平臺(tái)，以促進(jìn)醫(yī)學(xué)領(lǐng)域的的進(jìn)步。該刊鼓勵(lì)先進(jìn)的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見解，或?qū)彶槎嗄陙砟硞€(gè)重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時(shí)報(bào)道醫(yī)學(xué)領(lǐng)域的最新進(jìn)展和新發(fā)現(xiàn)新突破等。該刊近一年被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn)：

預(yù)計(jì)審稿時(shí)間：約2月約7周
國(guó)際TOP期刊
醫(yī)學(xué)
PHARMACOLOGY & PHARMACY
SCIE
中科院2區(qū)
預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）Biomedicine & Pharmacotherapy Cite Score數(shù)據(jù)

CiteScore：11.9
SJR：1.493
SNIP：1.409

學(xué)科類別	分區(qū)	排名	百分位
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Pharmacology	Q1	28 / 313	91%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評(píng)價(jià)期刊影響力的文獻(xiàn)計(jì)量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫中收集的引文為基礎(chǔ)，針對(duì)的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評(píng)價(jià)期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標(biāo)來評(píng)價(jià)。

歷年Cite Score趨勢(shì)圖

中科院SCI分區(qū)Biomedicine & Pharmacotherapy 中科院分區(qū)

中科院 2023年12月升級(jí)版 綜述期刊：否 Top期刊：是

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	2區(qū)	PHARMACOLOGY & PHARMACY 藥學(xué) MEDICINE, RESEARCH & EXPERIMENTAL 醫(yī)學(xué)：研究與實(shí)驗(yàn)	1區(qū) 2區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運(yùn)用科學(xué)計(jì)量學(xué)方法對(duì)國(guó)際、國(guó)內(nèi)學(xué)術(shù)期刊依據(jù)影響力進(jìn)行等級(jí)劃分的期刊評(píng)價(jià)標(biāo)準(zhǔn)。它為我國(guó)科研、教育機(jī)構(gòu)的管理人員、科研工作者提供了一份評(píng)價(jià)國(guó)際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國(guó)各地高校、科研機(jī)構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個(gè)層次，類似于“優(yōu)、良、及格”等。最開始，這個(gè)分區(qū)只是為了方便圖書管理及圖書情報(bào)領(lǐng)域的研究和期刊評(píng)估。之后中科院分區(qū)逐步發(fā)展成為了一種評(píng)價(jià)學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢(shì)圖

JCR分區(qū)Biomedicine & Pharmacotherapy JCR分區(qū)

2023-2024 年最新版

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：MEDICINE, RESEARCH & EXPERIMENTAL	SCIE	Q1	21 / 189	89.2%
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q1	15 / 354	95.9%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：MEDICINE, RESEARCH & EXPERIMENTAL	SCIE	Q1	18 / 189	90.74%
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q1	25 / 354	93.08%

JCR分區(qū)的優(yōu)勢(shì)在于它可以幫助讀者對(duì)學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評(píng)估。不同學(xué)科的文章引用量可能存在較大的差異，此時(shí)單獨(dú)依靠影響因子(IF)評(píng)價(jià)期刊的質(zhì)量可能是存在一定問題的。因此，JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢(shì)圖

發(fā)文數(shù)據(jù)

2023-2024 年國(guó)家/地區(qū)發(fā)文量統(tǒng)計(jì)

國(guó)家/地區(qū)數(shù)量
CHINA MAINLAND3044
India287
Iran257
USA234
Brazil205
Egypt143
South Korea98
Saudi Arabia85
Italy66
Australia65

本刊中國(guó)學(xué)者近年發(fā)表論文

1、Attenuated WNV-poly(A) exerts a broad-spectrum oncolytic effect by selective virus replication and CD8+T cell-dependent immune response
Author: Liu, Jing; Hu, Yan-Yan; Zhang, Qiu-Yan; Zhang, Ya-Nan; Li, Na; Zhang, Zhe-Rui; Zhan, Shun-Li; Gao, Lei; Deng, Cheng-Lin; Li, Xiao-Dan; Yuan, Shao-Peng; He, Yuan-Qiao; Ye, Han-Qing; Zhang, Bo

Journal: BIOMEDICINE & PHARMACOTHERAPY. 2023; Vol. 158, Issue , pp. -. DOI: 10.1016/j.biopha.2022.114094
2、Glutathione improves testicular spermatogenesis through inhibiting oxidative stress, mitochondrial damage, and apoptosis induced by copper deposition in mice with Wilson disease
Author: Chen, Kuiyu; Wu, Limin; Liu, Qianzhuo; Tan, Fang; Wang, Luyao; Zhao, Dan; Fang, Xinru; Liu, Xiang; Liu, Jiabo; Han, Hui

Journal: BIOMEDICINE & PHARMACOTHERAPY. 2023; Vol. 158, Issue , pp. -. DOI: 10.1016/j.biopha.2022.114107
3、Arctium lappa (Burdock): Insights from ethnopharmacology potential, chemical constituents, clinical studies, pharmacological utility and nanomedicine
Author: Yosri, Nermeen; Alsharif, Sultan M.; Xiao, Jianbo; Musharraf, Syed G.; Zhao, Chao; Saeed, Aamer; Gao, Ruichang; Said, Noha S.; Di Minno, Alessandro; Daglia, Maria; Guo, Zhiming; Khalifa, Shaden A. M.; El-Seedi, Hesham R.

Journal: BIOMEDICINE & PHARMACOTHERAPY. 2023; Vol. 158, Issue , pp. -. DOI: 10.1016/j.biopha.2022.114104
4、A novel inhibitor of PGK1 suppresses the aerobic glycolysis and proliferation of hepatocellular carcinoma
Author: Li, Mingfeng; Zhang, Aotong; Qi, Xin; Yu, Rilei; Li, Jing

Journal: BIOMEDICINE & PHARMACOTHERAPY. 2023; Vol. 158, Issue , pp. -. DOI: 10.1016/j.biopha.2022.114115
5、Sodium tanshinone IIA sulfonate protects against hyperhomocysteine-induced vascular endothelial injury via activation of NNMT/SIRT1-mediated NRF2/HO-1 and AKT/MAPKs signaling in human umbilical vascular endothelial cells
Author: Zhou, Zhong-Yan; Shi, Wen-Ting; Zhang, Jing; Zhao, Wai-Rong; Xiao, Ying; Zhang, Kai-Yu; Ma, Jie; Tang, Jing-Yi; Wang, Yu

Journal: BIOMEDICINE & PHARMACOTHERAPY. 2023; Vol. 158, Issue , pp. -. DOI: 10.1016/j.biopha.2022.114137
6、Attenuation of hyperglycemia-associated dyslipidemic, oxidative, cognitive, and inflammatory crises via modulation of neuronal ChEs/NF-kappa B/COX-2/NOx, and hepatorenal functional deficits by the Tridax procumbens extract
Author: Hogan, Itam Ako; Kuo, Yu-Cheng; Abubakar, Asmau N.; Lawal, Bashir; Agboola, Abdulhakeem R.; Lukman, Halimat Yusuf; Onikanni, Sunday Amos; Olawale, Femi; Fadaka, Adewale Oluwaseun; Ibrahim, Yunusa O.; Babalola, Shukurat B.; Batiha, Gaber El -Saber; Albogami, Sarah M.; Alorabi, Mohammed; De Waard, Michel; Huang, Hsu-Shan

Journal: BIOMEDICINE & PHARMACOTHERAPY. 2023; Vol. 158, Issue , pp. -. DOI: 10.1016/j.biopha.2022.114114
7、Exercise induced meteorin-like protects chondrocytes against inflammation and pyroptosis in osteoarthritis by inhibiting PI3K/Akt/NF-kappa B and NLRP3/caspase-1/GSDMD signaling
Author: Liu, Jiabao; Jia, Shuangshuo; Yang, Yue; Piao, Longhuan; Wang, Ziyuan; Jin, Zhuangzhuang; Bai, Lunhao

Journal: BIOMEDICINE & PHARMACOTHERAPY. 2023; Vol. 158, Issue , pp. -. DOI: 10.1016/j.biopha.2022.114118
8、Revealment study on the regulation of lipid metabolism by Lingguizhugan Decoction in heart failure treatment based on integrated lipidomics and proteomics
Author: Wang, Xu; Gao, Yanhua; Zhang, Jia; Zhang, Huaxing; Sun, Shuo; Su, Suwen; Kong, Dezhi; Wang, Qiao

Journal: BIOMEDICINE & PHARMACOTHERAPY. 2023; Vol. 158, Issue , pp. -. DOI: 10.1016/j.biopha.2022.114066